Business Context and Reporting Period
This Form 6-K is filed by Alterity Therapeutics Limited, a development stage enterprise headquartered in Melbourne, Australia. The report covers the month of January 2022 and was signed on January 4, 2022, by Geoffrey P. Kempler, Chairman.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document does not contain financial statements or performance metrics for the reporting period.
Material Changes
No material financial changes versus a prior comparable period are disclosed in this filing. The document serves primarily as a vehicle to submit exhibits regarding director interests rather than to report operational or financial variances.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or specific risk disclosures. The primary content is the submission of Exhibit 99.1, which consists of two Final Director's Interest Notices. The filing is incorporated by reference into various Registration Statements on Form S-8 and Form F-3.
Investor Verification Checklist
- Verify the details of the Director's Interest Notices submitted as Exhibit 99.1.
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential equity issuance.
- Review the company's most recent Form 20-F for actual financial performance data, as this 6-K contains none.